Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
artemether + lumefantrine
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04300309 CALINA (CCOA566B2307)
Malaria, uncomplicated (<5kg patients)
Phase 3
Artemether Cmax
Target Patients
Read-out Milestone(s)
Experimental: artemether lumefantrine (2.5 mg:30 mg)
artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose
Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium
falciparum malaria
Primary outcome measure: 2023
Publication
TBD
References
Abbreviations
Hematology
Biosimilars
Global Health
118 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation